Obesity – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Obesity – Pipeline Review, H1 2017’, provides an overview of the Obesity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Obesity

The report reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Obesity therapeutics and enlists all their major and minor projects

The report assesses Obesity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Obesity

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Obesity

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abeome Corp

Adamas Pharmaceuticals Inc

Advinus Therapeutics Ltd

Aegis Therapeutics LLC

Akron Molecules AG

Alize Pharma SAS

Amabiotics SAS

Amgen Inc

Aoxing Pharmaceutical Company Inc

Arrowhead Pharmaceuticals Inc

AstraZeneca Plc

Asubio Pharma Co Ltd

Athersys Inc

Biophytis SAS

BioRestorative Therapies Inc

Biozeus

Boehringer Ingelheim GmbH

Braasch Biotech LLC

C3J Therapeutics Inc

Camurus AB

Carmot Therapeutics Inc

CohBar Inc

CoMentis Inc

Connexios Life Sciences Pvt Ltd

ConSynance Therapeutics Inc

Corium International Inc

Daiichi Sankyo Company Ltd

DiscoveryBiomed Inc

Eisai Co Ltd

Eli Lilly and Company

Esperion Therapeutics Inc

Eternygen GmbH

Evotec AG

F. Hoffmann-La Roche Ltd

FibroGen Inc

Genmedica Therapeutics SL

Gila Therapeutics Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Glucox Biotech AB

GTx Inc

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Hyundai Pharmaceutical Co Ltd

Immungenetics AG

Intarcia Therapeutics Inc

Ionis Pharmaceuticals Inc

Ixchel Pharma LLC

Jenrin Discovery Inc

Johnson & Johnson

Laboratorios Silanes SA de CV

Lead Discovery Center GmbH

Leading BioSciences Inc

Lotus Pharmaceutical Co Ltd

M Pharmaceutical Inc

Magnus Life Ltd

MedImmune LLC

Merck & Co Inc

Mitochon Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

NeuroNano Pharma Inc

NGM Biopharmaceuticals Inc

NIBEC

Nordic Bioscience A/S

Novartis AG

Novo Nordisk A/S

ObeTherapy Biotechnology

Omeros Corp

OPKO Biologics Ltd

OPKO Health Inc

Pfizer Inc

PharmaIN Corp

Poxel SA

Progenra Inc

Prometheon Pharma LLC

ReCyte Therapeutics Inc

Renova Therapeutics Inc

Reviva Pharmaceuticals Inc

Saniona AB

Sanofi

Seoul Pharma Co Ltd

Shionogi & Co Ltd

Sinil Pharmaceutical Co Ltd

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Takeda Pharmaceutical Company Ltd

Toray Industries Inc

Umecrine AB

Vicore Pharma AB

Viking Therapeutics Inc

WhanIn Pharmaceutical Co Ltd

Xenetic Biosciences Inc

XL-protein GmbH

Yuyu Pharma Inc

Zafgen Inc

Zealand Pharma AS

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Obesity - Overview 7

Obesity - Therapeutics Development 8

Obesity - Therapeutics Assessment 36

Obesity - Companies Involved in Therapeutics Development 54

Obesity - Drug Profiles 104

Obesity - Dormant Projects 439

Obesity - Discontinued Products 453

Obesity - Product Development Milestones 457

Appendix 467

List of Tables

List of Tables

Number of Products under Development for Obesity, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Obesity – Pipeline by Abeome Corp, H1 2017

Obesity – Pipeline by Adamas Pharmaceuticals Inc, H1 2017

Obesity – Pipeline by Advinus Therapeutics Ltd, H1 2017

Obesity – Pipeline by Aegis Therapeutics LLC, H1 2017

Obesity – Pipeline by Akron Molecules AG, H1 2017

Obesity – Pipeline by Alize Pharma SAS, H1 2017

Obesity – Pipeline by Amabiotics SAS, H1 2017

Obesity – Pipeline by Amgen Inc, H1 2017

Obesity – Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017

Obesity – Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017

Obesity – Pipeline by AstraZeneca Plc, H1 2017

Obesity – Pipeline by Asubio Pharma Co Ltd, H1 2017

Obesity – Pipeline by Athersys Inc, H1 2017

Obesity – Pipeline by Biophytis SAS, H1 2017

Obesity – Pipeline by BioRestorative Therapies Inc, H1 2017

Obesity – Pipeline by Biozeus, H1 2017

Obesity – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Obesity – Pipeline by Braasch Biotech LLC, H1 2017

Obesity – Pipeline by C3J Therapeutics Inc, H1 2017

Obesity – Pipeline by Camurus AB, H1 2017

Obesity – Pipeline by Carmot Therapeutics Inc, H1 2017

Obesity – Pipeline by CohBar Inc, H1 2017

Obesity – Pipeline by CoMentis Inc, H1 2017

Obesity – Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017

Obesity – Pipeline by ConSynance Therapeutics Inc, H1 2017

Obesity – Pipeline by Corium International Inc, H1 2017

Obesity – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Obesity – Pipeline by DiscoveryBiomed Inc, H1 2017

Obesity – Pipeline by Eisai Co Ltd, H1 2017

Obesity – Pipeline by Eli Lilly and Company, H1 2017

Obesity – Pipeline by Esperion Therapeutics Inc, H1 2017

Obesity – Pipeline by Eternygen GmbH, H1 2017

Obesity – Pipeline by Evotec AG, H1 2017

Obesity – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Obesity – Pipeline by FibroGen Inc, H1 2017

Obesity – Pipeline by Genmedica Therapeutics SL, H1 2017

Obesity – Pipeline by Gila Therapeutics Inc, H1 2017

Obesity – Pipeline by Gilead Sciences Inc, H1 2017

Obesity – Pipeline by GlaxoSmithKline Plc, H1 2017

Obesity – Pipeline by Glucox Biotech AB, H1 2017

Obesity – Pipeline by GTx Inc, H1 2017

Obesity – Pipeline by HanAll Biopharma Co Ltd, H1 2017

Obesity – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Obesity – Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017

Obesity – Pipeline by Immungenetics AG, H1 2017

Obesity – Pipeline by Intarcia Therapeutics Inc, H1 2017

Obesity – Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Obesity – Pipeline by Ixchel Pharma LLC, H1 2017

Obesity – Pipeline by Jenrin Discovery Inc, H1 2017

Obesity – Pipeline by Johnson & Johnson, H1 2017

Obesity – Pipeline by Laboratorios Silanes SA de CV, H1 2017

Obesity – Pipeline by Lead Discovery Center GmbH, H1 2017

Obesity – Pipeline by Leading BioSciences Inc, H1 2017

Obesity – Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017

Obesity – Pipeline by M Pharmaceutical Inc, H1 2017

Obesity – Pipeline by Magnus Life Ltd, H1 2017

Obesity – Pipeline by MedImmune LLC, H1 2017

Obesity – Pipeline by Merck & Co Inc, H1 2017

Obesity – Pipeline by Mitochon Pharmaceuticals Inc, H1 2017

Obesity – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Obesity – Pipeline by NeuroNano Pharma Inc, H1 2017

Obesity – Pipeline by NGM Biopharmaceuticals Inc, H1 2017

Obesity – Pipeline by NIBEC, H1 2017

Obesity – Pipeline by Nordic Bioscience A/S, H1 2017

Obesity – Pipeline by Novartis AG, H1 2017

Obesity – Pipeline by Novo Nordisk A/S, H1 2017

Obesity – Pipeline by ObeTherapy Biotechnology, H1 2017

Obesity – Pipeline by Omeros Corp, H1 2017

Obesity – Pipeline by OPKO Biologics Ltd, H1 2017

Obesity – Pipeline by OPKO Health Inc, H1 2017

Obesity – Pipeline by Pfizer Inc, H1 2017

Obesity – Pipeline by PharmaIN Corp, H1 2017

Obesity – Pipeline by Poxel SA, H1 2017

Obesity – Pipeline by Progenra Inc, H1 2017

Obesity – Pipeline by Prometheon Pharma LLC, H1 2017

Obesity – Pipeline by ReCyte Therapeutics Inc, H1 2017

Obesity – Pipeline by Renova Therapeutics Inc, H1 2017

Obesity – Pipeline by Reviva Pharmaceuticals Inc, H1 2017

Obesity – Pipeline by Saniona AB, H1 2017

Obesity – Pipeline by Sanofi, H1 2017

Obesity – Pipeline by Seoul Pharma Co Ltd, H1 2017

Obesity – Pipeline by Shionogi & Co Ltd, H1 2017

Obesity – Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017

Obesity – Pipeline by Sorrento Therapeutics Inc, H1 2017

Obesity – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Obesity – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Obesity – Pipeline by Toray Industries Inc, H1 2017

Obesity – Pipeline by Umecrine AB, H1 2017

Obesity – Pipeline by Vicore Pharma AB, H1 2017

Obesity – Pipeline by Viking Therapeutics Inc, H1 2017

Obesity – Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017

Obesity – Pipeline by Xenetic Biosciences Inc, H1 2017

Obesity – Pipeline by XL-protein GmbH, H1 2017

Obesity – Pipeline by Yuyu Pharma Inc, H1 2017

Obesity – Pipeline by Zafgen Inc, H1 2017

Obesity – Pipeline by Zealand Pharma AS, H1 2017

Obesity – Dormant Projects, H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..1), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..2), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..3), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..4), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..5), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..6), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..7), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..8), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..9), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..10), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..11), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..12), H1 2017

Obesity – Dormant Projects, H1 2017 (Contd..13), H1 2017

Obesity – Discontinued Products, H1 2017

Obesity – Discontinued Products, H1 2017 (Contd..1), H1 2017

Obesity – Discontinued Products, H1 2017 (Contd..2), H1 2017

Obesity – Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures

List of Figures

Number of Products under Development for Obesity, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports